In:
American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology (ASCO), , No. 38 ( 2018-05), p. 249-261
Kurzfassung:
PRACTICAL APPLICATIONS The Cancer Genome Atlas project proposes the division of gastric cancer into four molecular subtypes: tumors positive for EBV (with recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, PD-L1, and PD-L2), microsatellite-instable tumors, genomically stable tumors, and tumors with chromosomal instability. MSI-H and high PD-L1 and PD-L2 expression raise the potential of immune therapy for patients with EBV-positive gastric cancer. HER2 overexpression in gastric cancer ranges from 9% to 23% and is more frequent in the intestinal subtype. Its prognostic value remains unclear, but HER2 should be tested in all patients with metastatic gastric cancer using an IHC-modified scoring system. Trastuzumab deruxtecan has shown important tumor activity in tumors harboring HER2 overexpression. Currently, there is a marginal benefit of apatinib (1.8 months) and ramucirumab (1.4–2.2 months) for advanced gastric cancer. Further research on biomarkers, drug combinations, sequencing, and maintenance therapies might produce more significant results on targeting VEGF.
Materialart:
Online-Ressource
ISSN:
1548-8748
,
1548-8756
Sprache:
Englisch
Verlag:
American Society of Clinical Oncology (ASCO)
Publikationsdatum:
2018
ZDB Id:
2431126-1
